Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
Debra A. Cafaro, Chairman and CEO of Ventas, Inc. (VTR), exercised 10,322 fully vested stock options on 09/02/2025 at an exercise price of $65.45 per share and simultaneously sold the 10,322 underlying shares under a Rule 10b5-1 trading plan entered 03/28/2024. The sales generated a weighted average sale price of $67.8031 per share. After these transactions the reporting person beneficially owns 1,145,695 shares and holds 681,287 unexercised options. The filing was signed on 09/04/2025 by an attorney-in-fact.
Ventas, Inc. (VTR) Form 144 notice reports a proposed sale of common stock by an insider and recent related sales. The filer indicates a broker-assisted sale of 10,322 shares valued at $699,863.18 to occur on 09/02/2025 on the NYSE. The filing states the shares were acquired the same day by exercise of employee stock options from Ventas, Inc.
The filing also discloses five common-stock sales by the same person during July–August 2025 totaling 31,990 shares with aggregate gross proceeds listed per sale (largest single prior sale: 14,753 shares for $967,822.54). Total shares outstanding is shown as 454,471,192, which provides context for the size of the proposed sale relative to the company.
Reporting person: Robert F. Probst, EVP and CFO of Ventas, Inc. (VTR). Transaction date: 08/04/2025; Form filed: 08/06/2025.
Actions: Probst exercised 29,691 fully vested stock options at an exercise price of $65.45 and sold 29,691 underlying shares pursuant to a Rule 10b5-1 trading plan entered on 02/19/2025. The shares were sold in multiple transactions at prices ranging $68.45–$68.5563 with a weighted average sale price of $68.4917.
Post-transaction position: Beneficial ownership reported as 168,364 shares held directly; 33,591 unexercised options remain (expiration 05/04/2026).